SB 132 is an omnibus insurance bill that makes broad changes across Alaska’s insurance code. It updates licensing, examination, reporting, and enforcement rules for insurers and insurance-related entities, including third-party administrators, pharmacy benefits managers, surplus lines brokers, independent adjusters, and reinsurance participants. The bill also revises filing deadlines, fee structures, notice requirements, and the director of insurance’s authority to examine and regulate these entities.
A major portion of the bill focuses on health insurance and pharmacy benefit regulation. It requires non-network options in certain network-based health plans, adds prior-authorization disclosure requirements for benefit-level exceptions, expands protections for consumers in pharmacy benefit arrangements, and prohibits practices such as spread pricing and certain reimbursement disparities. It also adds or revises coverage rules for emergency services, referrals, breast cancer screening, colorectal cancer screening, and cancellation/nonrenewal notice periods, while creating a new prohibition on insurance decisions based solely on elected official status.
The bill also changes several property, casualty, and specialty insurance provisions. It bars depreciation of labor in residential property claims except in limited endorsement situations, adjusts rules for cancellation and nonrenewal of property and casualty policies, modifies surplus lines and nonadmitted insurer rules, and updates provisions governing owner-controlled and contractor-controlled insurance programs. In addition, it revises tax and reporting rules for insurers, risk retention groups, and surplus lines transactions, and it changes the treatment of certain reinsurance and valuation standards.
Overall, the bill’s impact is to expand state oversight of insurance intermediaries and PBMs, tighten consumer protections in health and property insurance, and modernize a wide range of statutory references and procedures. It also converts some registration concepts to licensing, adds new compliance and disclosure obligations, and sets new fees for third-party administrators and pharmacy benefits managers. Most provisions take effect January 1, 2026, with some construction-related sections taking effect immediately.
The bill appears to have had strong bipartisan support and little visible opposition in the recorded votes, passing the Senate 19-0, the House 40-0, and Senate concurrence 20-0. The lack of recorded dissent suggests general agreement on the need to update insurance regulation and consumer protections. Because no committee transcripts were provided, there is no documented floor or committee debate to identify specific arguments, but the breadth of the bill indicates it was treated as a comprehensive technical-and-policy package rather than a narrowly contested measure.
SB 132 amends numerous provisions in Titles 12 and 21 of Alaska law, especially the insurance code, by creating new licensing regimes for third-party administrators and pharmacy benefits managers, revising insurer examination and reporting authority, changing premium tax and surplus lines rules, and adding consumer-protection standards for health, property, casualty, and specialty insurance products. It also repeals several outdated provisions and updates cross-references, deadlines, and enforcement mechanisms. Affected parties include insurers, health care insurers, HMOs, PBMs, TPAs, surplus lines brokers, reinsurance participants, independent adjusters, and policyholders.
The recorded vote history shows unanimous or near-unanimous support in both chambers, indicating broadly favorable sentiment toward the bill. The measure’s omnibus nature and the absence of recorded dissent suggest it was viewed as a necessary modernization of insurance regulation and consumer protections rather than a controversial policy shift. No committee transcripts were provided, so there is no documented opposition or amendment debate in the supplied materials.
No specific contention is documented in the provided transcripts, but the bill’s most likely pressure points are the new regulatory burdens and fees on pharmacy benefits managers and third-party administrators, the restrictions on PBM pricing and reimbursement practices, and the expanded authority of the insurance director. Other potentially sensitive provisions include the prohibition on insurance decisions based on elected-official status, the labor-depreciation rule for residential property claims, and the new coverage and notice requirements for health plans. The unanimous votes suggest any disagreements were either resolved in committee or not significant enough to affect final passage.